Where each candidate actually stands
One view of the programmes we are funding, with the phase gate each one is sitting at. We publish the early ones as openly as the late ones.
| Code | Therapeutic area | Modality | Phase | Status |
|---|---|---|---|---|
| PM-101 | Cardiology | Small molecule | Phase II | Enrolling |
| PM-048 | Cardiology | Extended-release formulation | Phase III | Ongoing |
| PM-212 | Antibiotics | Small molecule | Phase II | Enrolling |
| PM-219 | Antibiotics | Conjugated biologic | Phase I | Initiating |
| PM-330 | Oncology | Precision biologic | Phase I | First dose |
| PM-007 | Oncology | Antibody fragment | Discovery | Preclinical |
Illustrative candidates — send us your real programme list and we will replace this table.
Reading the phases
A candidate only moves when its pre-registered readout clears. Discovery programmes are internal; Phase I is the first point at which a compound has been given to people.
For partners
Licensing, co-development and supply conversations start with our business development team, who can share diligence packs under a mutual NDA.